Related Experiment Videos
Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer
Abstract:
Dihydrotestosterone (DHT) levels were measured by RIA in tumor tissue from 32 men with advanced prostate cancer and correlated with their clinical responses to antiandrogen therapy. In 24 patients with tumor tissue DHT levels greater than 2.5 ng/g, 20 initially responded to therapy with partial objective regression or were objectively stable for 12 or more months, while 4 patients relapsed in less than 1 yr. The average disease-free interval in this group was 24 months, with 9 patients still continuing in partial objective regression or objective stability. Of 8 patients with DHT levels less than 2.0 ng/g, 5 had either objective progression or were objectively stable for 6 months or less; 2 other patients have completed remissions ranging from 16-24 months, while 1 patient remains objectively stable for 21 months to date. The average disease-free interval in patients with DHT levels less than 2.0 ng/g was 9.75 months, which is significantly less (P less than 0.001) than that of patients with DHT levels greater than 2.5 ng/g. There was no discernible relationship between the Gleason histological grade of prostate cancer and initial clinical response to therapy in these same patients. In summary, this study supports the thesis that tissue DHT levels may be a useful marker for predicting the clinical response of prostate cancer to antiandrogen therapy.
Insights
Higher dihydrotestosterone (DHT) levels in prostate cancer tissue predict better response to antiandrogen therapy. Measuring DHT may help personalize treatment for advanced prostate cancer patients.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Advanced prostate cancer treatment often involves antiandrogen therapy.
- Predicting patient response to antiandrogen therapy is crucial for effective management.
Purpose of the Study:
- To investigate the correlation between intratumoral dihydrotestosterone (DHT) levels and clinical response to antiandrogen therapy in advanced prostate cancer.
- To determine if DHT levels can serve as a predictive biomarker for treatment outcomes.
Main Methods:
- Radioimmunoassay (RIA) was used to measure DHT levels in tumor tissue from 32 men with advanced prostate cancer.
- Clinical responses, including objective regression, stable disease, and progression, were correlated with pre-treatment DHT levels.
Main Results:
- Patients with DHT levels >2.5 ng/g showed significantly longer disease-free intervals (average 24 months) compared to those with DHT levels <2.0 ng/g (average 9.75 months).
- A higher proportion of patients with elevated DHT levels experienced prolonged objective responses or stable disease.
- No significant correlation was found between Gleason histological grade and initial clinical response.
Conclusions:
- Intratumoral DHT levels appear to be a valuable predictive marker for the efficacy of antiandrogen therapy in advanced prostate cancer.
- Measuring tissue DHT may aid in selecting appropriate treatments and improving patient outcomes.